Literature DB >> 20850245

Inflammatory imaging with ultrasmall superparamagnetic iron oxide.

Taro Matsushita1, Yoshinori Kusakabe, Hitomi Fujii, Katsutoshi Murase, Youichi Yamazaki, Kenya Murase.   

Abstract

The purpose of this study was to investigate the usefulness and feasibility of magnetic resonance imaging (MRI) with ultrasmall superparamagnetic iron oxide (USPIO) (USPIO-enhanced MRI) for imaging inflammatory tissues. First, we investigated the relationship between the apparent transverse relaxation rate (R2*) and the concentration of USPIO by phantom studies and measured the apparent transverse relaxivity (r2*) of USPIO. Second, we performed animal experiments using a total of 30 mice. The mice were divided into five groups [A (n=6), B (n=6), C (n=6), sham control (n=6), and control (n=6)]. The mice in Groups A, B, C and control were subcutaneously injected with 0.1 ml of turpentine oil on Day 0, while those in the sham control group were subcutaneously injected with 0.1 ml of saline. The mice in Groups A, B, C and sham control were intraperitoneally injected with 200 μmol Fe per kilogram body weight of USPIO (28 nm in diameter) immediately after the first MRI study on Days 3, 5, 7 and 7, respectively, and those in the control group were not injected with USPIO. The second and third MRI studies were performed at 24 and 48 h after USPIO administration, respectively. The maps of R2* were generated from the apparent transverse relaxation time (T2*)-weighted images with six different echo times. The phantom studies showed that there was a linear relationship between R2* and the concentration of USPIO (r=0.99) and the r2* value of USPIO was 105.7 mM(-1) s(-1). There was a significant increase of R2* in inflammatory tissues in Group C at 24 h after USPIO administration compared with the precontrast R2* value. Our results suggest that USPIO-enhanced MRI combined with R2* measurement is useful for detecting inflammatory tissues.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20850245     DOI: 10.1016/j.mri.2010.08.005

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  8 in total

1.  Imaging of Her2-targeted magnetic nanoparticles for breast cancer detection: comparison of SQUID-detected magnetic relaxometry and MRI.

Authors:  Natalie L Adolphi; Kimberly S Butler; Debbie M Lovato; T E Tessier; Jason E Trujillo; Helen J Hathaway; Danielle L Fegan; Todd C Monson; Tyler E Stevens; Dale L Huber; Jaivijay Ramu; Michelle L Milne; Stephen A Altobelli; Howard C Bryant; Richard S Larson; Edward R Flynn
Journal:  Contrast Media Mol Imaging       Date:  2012 May-Jun       Impact factor: 3.161

Review 2.  Iron-based superparamagnetic nanoparticle contrast agents for MRI of infection and inflammation.

Authors:  Alexander Neuwelt; Navneet Sidhu; Chien-An A Hu; Gary Mlady; Steven C Eberhardt; Laurel O Sillerud
Journal:  AJR Am J Roentgenol       Date:  2015-03       Impact factor: 3.959

3.  Biodistribution and Clearance of Stable Superparamagnetic Maghemite Iron Oxide Nanoparticles in Mice Following Intraperitoneal Administration.

Authors:  Binh T T Pham; Emily K Colvin; Nguyen T H Pham; Byung J Kim; Emily S Fuller; Elizabeth A Moon; Raphael Barbey; Samuel Yuen; Barry H Rickman; Nicole S Bryce; Stephanie Bickley; Marcel Tanudji; Stephen K Jones; Viive M Howell; Brian S Hawkett
Journal:  Int J Mol Sci       Date:  2018-01-10       Impact factor: 5.923

4.  Impact of surface coating and particle size on the uptake of small and ultrasmall superparamagnetic iron oxide nanoparticles by macrophages.

Authors:  Shigeyoshi Saito; Mana Tsugeno; Daichi Koto; Yuki Mori; Yoshichika Yoshioka; Satoshi Nohara; Kenya Murase
Journal:  Int J Nanomedicine       Date:  2012-10-10

Review 5.  Iron Oxide as an MRI Contrast Agent for Cell Tracking.

Authors:  Daniel J Korchinski; May Taha; Runze Yang; Nabeela Nathoo; Jeff F Dunn
Journal:  Magn Reson Insights       Date:  2015-10-06

6.  Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent.

Authors:  Sandeep S Hedgire; Shaunagh McDermott; Gregory R Wojtkiewicz; Seyed Mahdi Abtahi; Mukesh Harisinghani; Jason L Gaglia
Journal:  Int J Nanomedicine       Date:  2014-04-28

Review 7.  The Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment Response.

Authors:  Matthew P Moy; Jenny Sauk; Michael S Gee
Journal:  Gastroenterol Res Pract       Date:  2015-12-27       Impact factor: 2.260

8.  Pre-Labeling of Immune Cells in Normal Bone Marrow and Spleen for Subsequent Cell Tracking by MRI.

Authors:  Gabrielle M Siegers; Shruti Krishnamoorthy; Laura E Gonzalez-Lara; Catherine McFadden; Yuhua Chen; Paula J Foster
Journal:  Tomography       Date:  2016-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.